A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation

BACKGROUND: AdGV.EGR.TNF.11D (TNFerade™ Biologic) is a replication-deficient adenoviral vector expressing human tumor necrosis factor alpha (TNF-α) under the control of the chemoradiation-inducible EGR-1 promoter. TNF-α has been shown to function as a radiation sensitizer. We conducted a phase I dos...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Seiwert, T. Y., Darga, T., Haraf, D., Blair, E. A., Stenson, K., Cohen, E. E. W., Salama, J. K., Villaflor, V., Witt, M. E., Lingen, M. W., Weichselbaum, R. R., Vokes, E. E.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2013
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC3662388/
https://ncbi.nlm.nih.gov/pubmed/23104721
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mds523
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller